{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-studies#webpage",
"url": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-studies",
"name": "Serving as an extended safety partner for an emerging biotech's vaccine studies",
"description": "This Fortrea case study explores how an emerging biotech managing vaccine studies scaled pharmacovigilance and clinical safety operations through an extended safety partnership model. The study involved operational requirements related to safety database hosting, end-to-end case processing, regulatory submissions, and global pharmacovigilance support during clinical and post-marketing vaccine activities. The case study highlights challenges related to rapid growth in safety case volumes, operational scalability, resource expansion, and maintaining regulatory compliance across vaccine safety operations. Fortrea supported the sponsor as an extended safety partner by implementing scalable workforce strategies, integrated case processing support, safety database management, and operational coordination aligned with evolving study demands. By integrating pharmacovigilance support with clinical safety operations and strategic resource management, the approach strengthened continuity across vaccine study activities and enabled management of a 12-fold increase in safety case volume within accelerated timelines."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Serving as an extended safety partner for an emerging biotech's vaccine studies",
"item": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-studies"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-studies#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-studies#webpage"
},
"headline": "Managing Rapid Safety Case Growth for an Emerging Biotech Vaccine Study | Fortrea Case Study",
"description": "This Fortrea case study explores how an emerging biotech managing vaccine studies scaled pharmacovigilance and clinical safety operations through an extended safety partnership model. The study involved operational requirements related to safety database hosting, end-to-end case processing, regulatory submissions, and global pharmacovigilance support during clinical and post-marketing vaccine activities. The case study highlights challenges related to rapid growth in safety case volumes, operational scalability, resource expansion, and maintaining regulatory compliance across vaccine safety operations. Fortrea supported the sponsor as an extended safety partner by implementing scalable workforce strategies, integrated case processing support, safety database management, and operational coordination aligned with evolving study demands. By integrating pharmacovigilance support with clinical safety operations and strategic resource management, the approach strengthened continuity across vaccine study activities and enabled management of a 12-fold increase in safety case volume within accelerated timelines.",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-11-15",
"dateModified": "2024-11-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-11/CS_0024_FSPX_Extended%20Safety%20Partner_0823_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}